<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034435</url>
  </required_header>
  <id_info>
    <org_study_id>131139</org_study_id>
    <nct_id>NCT02034435</nct_id>
  </id_info>
  <brief_title>Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism</brief_title>
  <official_title>Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim 1.Test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone
      system impairs glycemic control via effects on insulin sensitivity and insulin secretion.

      Aim 2. Test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone
      system impairs insulin secretion and insulin sensitivity via an mineralocorticoid-receptor
      dependent mechanism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In aim 1 subjects are randomized to cross over between an 8 day high salt and 8 day low salt
      diet and assessments are made.

      In aim 2, subjects are randomized to a 2x2 cross over study with an 8 day low salt diet and
      either eplerenone 50mg or amlodipine 5mg.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>After 8 days of diet</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>after 8 days of diet</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Aim1-Low salt diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim 1-high salt diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim2- low salt diet and epleronone-amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects on a low salt diet will receive epleronone 50mg for 8 days and assessments will be made, then cross over to a low salt diet with amlodipine 5mg for 8days and assessments will be made.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aim2- lowsaltdiet and amlodipine-epleronone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects on a low salt diet will receive amlodipine 5mg for 8 days and assessments will be made, then cross over to a low salt diet with epleronone 50mg for 8days and assessments will be made.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>glucose and insulin testing</intervention_name>
    <arm_group_label>Aim1-Low salt diet</arm_group_label>
    <arm_group_label>Aim 1-high salt diet</arm_group_label>
    <arm_group_label>Aim2- low salt diet and epleronone-amlodipine</arm_group_label>
    <arm_group_label>aim2- lowsaltdiet and amlodipine-epleronone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ambulatory subjects, 18 to 70 years of age, inclusive

          2. For female subjects, the following conditions must be met:

               1. postmenopausal status for at least 1 year, or

               2. status-post surgical sterilization, or

               3. if of childbearing potential, utilization of adequate birth control and
                  willingness to undergo urine beta-hcg testing prior to drug treatment and on
                  every study day.

          3. Metabolic Syndrome as defined by the presence of &gt; 3 of the following:

               1. Systolic Blood Pressure &gt; 130 mm Hg OR Diastolic Blood Pressure &gt; 85 mm Hg.

               2. Glucose Intolerance (Fasting Plasma Glucose â‰¥ 100 mg/dL)

               3. Increased triglyceride level &gt; 150mg/dL (1.7mmol/L)

               4. Decreased levels of HDL cholesterol (For males, less than 40 mg/dL; For females,
                  less than 50 mg/dL)

               5. Waist circumference (For males, greater than 40 inches; For females, greater than
                  35 inches)

        Exclusion Criteria:

          1. type 1 Diabetes

          2. Type II Diabetes

          3. Impaired renal function

          4. Prior allergies to medications used in the study protocol

          5. Screening plasma potassium &gt;5.5 mmol/L or sodium &lt;135 mmol/L

          6. Cardiovascular disease

          7. Use of hormone replacement therapy

          8. Breast-feeding

          9. Treatment with anticoagulants

         10. History of serious neurologic disease

         11. History or presence of immunological or hematological disorders

         12. Diagnosis of asthma requiring use of inhaled beta agonist

         13. Clinically significant gastrointestinal impairment

         14. Impaired hepatic function

         15. Hematocrit &lt;35%

         16. Any underlying or acute disease requiring regular medication which could possibly pose
             a threat to the subject or make implementation of the protocol or interpretation of
             the study results difficult, such as arthritis treated with non-steroidal
             antiinflammatory drugs

         17. Treatment with chronic systemic glucocorticoid therapy

         18. Treatment with lithium salts

         19. History of alcohol or drug abuse

         20. Treatment with any investigational drug in the 1 month preceding

         21. Mental conditions rendering the subject unable to understand the nature, scope and
             possible consequences of the study

         22. Inability to comply with the protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James M Luther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Loretta Byrne, RN</last_name>
    <phone>615-322-2105</phone>
    <email>loretta.byrne@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loretta Byrne, RN</last_name>
      <phone>615-322-2105</phone>
      <email>loretta.byrne@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Holly Waldrop</last_name>
      <email>holly.waldrop@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James M Luther, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>James Matt Luther</investigator_full_name>
    <investigator_title>M.D., MSCI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

